Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...

Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...

Meanwhile, in a recent clinical trial, Amgen's experimental weight-loss drug fell short of expectations, causing a 12% dip in ...

The proposed rule could give millions of Americans access to the new drugs; it will also put pressure on the incoming Trump administration.

PTC Therapeutics said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of fatal neurodegenerative disease called amyotrophic lateral sclerosis.

Amgen Obesity Drug Cut Weight In Closely Watched Study Study ... that the company is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that it is ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...